Skye Bioscience to Present Poster at Keystone Obesity Conference
Rhea-AI Summary
Skye Bioscience (Nasdaq: SKYE) will present a poster at the Keystone Obesity conference on Jan 28, 2026 addressing nimacimab, a peripherally‑restricted CB1‑inhibitor antibody, in diet induced obesity models.
Presentation covers nimacimab alone, combined with tirzepatide, durability after treatment stop, maintenance use post‑tirzepatide, and role of caloric restriction. Presenting author: Chris Twitty, PhD. Poster session 2, poster number 2020, at 7:30 PM.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
SKYE was down 2.71% while close peers were mixed: AVTX +1.09%, CRDF +1.44%, FBRX -8.9%, HURA -8.47%, ZURA +7.05%. This points to stock-specific trading rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Corporate outlook | Positive | -4.0% | Outlined 2026 nimacimab milestones and development plans. |
| Jan 05 | Collaboration deal | Positive | -2.3% | Halozyme ENHANZE license for higher-dose nimacimab delivery. |
| Nov 24 | Investor conferences | Neutral | +11.6% | Participation in multiple December healthcare investor conferences. |
| Nov 10 | Earnings & trial | Neutral | -7.2% | Q3 2025 results and CBeyond Phase 2a combination data update. |
| Nov 05 | Clinical data | Positive | +6.3% | Late-breaking ObesityWeek oral on rebound weight gain data. |
Recent history shows several instances where seemingly positive strategic or clinical updates were followed by negative price reactions, while conference visibility and detailed trial data drew more supportive responses.
Over the past few months, Skye has focused on nimacimab for obesity and metabolic disorders, with key milestones such as CBeyond Phase 2a data, a 26-week extension update expected in Q1 2026, and plans for a Phase 2b trial in Q3 2026. A collaboration with Halozyme on ENHANZE-enabled delivery and multiple obesity-focused conference presentations underscored the program’s profile. Today’s Keystone obesity poster continues this pattern of scientific and visibility-focused updates following prior data and corporate outlook communications.
Market Pulse Summary
This announcement centers on a Keystone conference poster exploring how nimacimab, a peripherally restricted CB1-inhibiting antibody, interacts with incretin-based therapies and affects durability of weight loss in a diet-induced obesity mouse model. It follows prior Phase 2a data and a collaboration aimed at higher-dose subcutaneous delivery. Investors may focus on how these preclinical and translational insights connect to upcoming human data and planned Phase 2b development in obesity.
Key Terms
tirzepatide medical
AI-generated analysis. Not financial advice.
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present a poster at Keystone’s conference, Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects.
Skye’s presentation addresses the following questions regarding the ability of its peripherally-restricted CB1-inhibitor antibody:
- Can nimacimab enhance optimal and suboptimal doses of incretin agonists?
- How durable is nimacimab’s effect on weight loss after treatment discontinuation?
- Can nimacimab be used as a maintenance therapy after tirzepatide discontinuation?
- Is caloric-restriction the primary mechanism of nimacimab-driven weight loss?
Presentation details:
Title: Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide Discontinuation in a Diet Induced Obesity (DIO) Mouse Model
Presenting Author: Chris Twitty, PhD
Poster Session: 2
Poster Number: 2020
Date: 1/28/2026
Time: 7:30:00 PM
About Nimacimab
Nimacimab is a potential first-in-class, peripherally-restricted monoclonal antibody inhibitor of the CB1 receptor. Unlike previous CB1-targeting drugs, nimacimab is designed to avoid central nervous system penetration, potentially limiting neuropsychiatric side effects seen with small-molecule antagonists. As a non-incretin, non-peptide agent, nimacimab acts independently of the GLP-1 pathway and has also demonstrated additive or complementary effects in combination with incretin-based therapies in preclinical and clinical studies.
Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FAQ
When will Skye Bioscience (SKYE) present the nimacimab poster at Keystone Obesity on January 28, 2026?
What questions will Skye Bioscience (SKYE) address about nimacimab in the Keystone poster?
Who is the presenting author for Skye Bioscience's (SKYE) Keystone Obesity poster?
What is the title of Skye Bioscience's (SKYE) poster at Keystone Obesity on 1/28/2026?
Which compound combinations does Skye Bioscience (SKYE) test in the Keystone poster?
